# Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases

> **NCT00103038** · NA · COMPLETED · sponsor: **OHSU Knight Cancer Institute** · enrollment: 155 (actual)

## Conditions studied

- Central Nervous System Lymphoma
- Malignant Glioma
- Metastatic Malignant Neoplasm in the Brain

## Interventions

- **PROCEDURE:** 3 Tesla Magnetic Resonance Imaging
- **PROCEDURE:** Dynamic Contrast-Enhanced Magnetic Resonance Imaging
- **PROCEDURE:** Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
- **DRUG:** Ferumoxytol
- **DRUG:** Gadolinium
- **PROCEDURE:** MRI-Based Angiogram

## Key facts

- **NCT ID:** NCT00103038
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06-04
- **Primary completion:** 2016-05-10
- **Final completion:** 2016-06-10
- **Target enrollment:** 155 (ACTUAL)
- **Last updated:** 2022-06-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00103038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00103038, "Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00103038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*